Alto Neuroscience (ANRO) Net Income towards Common Stockholders (2023 - 2026)

Alto Neuroscience has disclosed Net Income towards Common Stockholders across 4 years of filings, most recently posting -$26.1 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$26.1 million, down 80.81% year-over-year; the trailing twelve-month figure through Mar 2026 was -$73.9 million (down 18.42% YoY), and the FY2025 annual result was -$62.2 million, down 1.79% from the prior year.
• Net Income towards Common Stockholders came in at -$26.1 million for Q1 2026 at Alto Neuroscience, down from -$16.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$7.3 million in Q1 2023 to a low of -$26.1 million in Q1 2026.
• The 4-year median for Net Income towards Common Stockholders is -$14.4 million (2025), against an average of -$14.3 million.
• Across the five-year window, Net Income towards Common Stockholders sank 82.47% in 2024 and climbed 15.93% in 2025, its largest moves.
• Alto Neuroscience's Net Income towards Common Stockholders stood at -$11.4 million in 2023, then sank by 33.49% to -$15.2 million in 2024, then declined by 5.75% to -$16.1 million in 2025, then slumped by 62.56% to -$26.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$26.1 million (Q1 2026), -$16.1 million (Q4 2025), and -$14.1 million (Q3 2025), per Business Quant data.